Clinical Trial Update: A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Phase 2 clinical study of MIL62 for Systemic Lupus Erythematosus, conducted by Beijing Mabworks Biotech Co., Ltd., currently listed as active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• MIL62

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: ACTIVE_NOT_RECRUITING